FINCB/571 Competency 2 Assessment and Rubric
eva.brisen
JohnsonJohnsonInvestorPresentation.pptx
Johnson & Johnson Investor Presentation
Welcome, everyone! Thank you for joining today’s session. Our goal is to provide investors with a comprehensive overview of Johnson & Johnson’s recent financial performance, current valuation, and forward-looking outlook, along with a strategic growth proposal designed to enhance shareholder value.
This presentation will cover:
Operating metrics and historical trends
Market valuation and stock performance
Cash flow and liquidity analysis
Dividend policy and shareholder returns
A strategic initiative for future growth
And finally, our investment recommendation
By the end of this discussion, you’ll have a clear picture of J&J’s strong fundamentals, its stability as a blue-chip investment, and the opportunities ahead for long-term growth.
1
Financial Performance, Growth Outlook, and New Product Strategy
Presenter: Mohammed Ali
Date: 10 December 2025
University of Phoenix
Class: FINCB/571: Corporate Finance
Company Overview & Business Segments
Business Segments:
Innovative Medicines (pharmaceuticals) + MedTech (medical devices & technology) — following the spinoff of the consumer-health division. CNBC+1
Global Presence:
Operations worldwide; diversified across therapeutic areas: immunology, oncology, neuroscience, cardiovascular, etc. CNBC
Corporate Strengths:
Strong R&D pipeline, robust cash flows, diversified revenue base, long history of dividend payments.
J&J’s shift to focus on higher-margin segments (after spinning off consumer health) strengthens its business model — more exposure to pharmaceuticals and MedTech which are growth- and innovation-driven.
Diversification across many therapeutic areas and medical devices helps spread risk (less dependence on any single product).
Its global footprint and brand recognition support consistent demand and market reach
2
Revenue Trend
J&J’s shift to focus on higher-margin segments (after spinning off consumer health) strengthens its business model — more exposure to pharmaceuticals and MedTech which are growth- and innovation-driven.
Diversification across many therapeutic areas and medical devices helps spread risk (less dependence on any single product).
Its global footprint and brand recognition support consistent demand and market reach
3
Key Performance Snapshot (2022–2024 + 2025 Q3)
Financial Metrics
| Metric / Period | 2022 | 2023 | 2024 | 2025 Q3 (YTD/Latest) |
| Revenue (USD) | n/a | US$ 85.16 B (JNJ.com) | US$ 88.82 B (JNJ.com) | Q3 2025 sales (quarterly) US$ 23.99 B; backlog strong. (JNJ.com) |
| Diluted EPS (GAAP) | — | — | US$ 5.79 (JNJ.com) | Q3 2025: US$ 2.12 (GAAP); Adj. EPS (non-GAAP) diluted ~ US$ 2.80. (JNJ.com) |
| Dividend per share (annual) | — | — | US$ 5.20 (most recent) (Twelve Data) | Dividend yield approx 2.9% (given share price). (CNBC) |
| Cash & Cash Equivalents (end of 2024) | — | — | US$ 24.1 B (JNJ.com) | 2025 Free Cash Flow YTD reported ~$14.2 B. (JNJ.com) |
Revenue has grown steadily; 2024 built on 2023 results.
Earnings per share show upward trend, supporting shareholder value.
The healthy dividend and consistent payout reflect commitment to returning capital.
Strong cash reserves and robust free cash flow provide flexibility for investment, R&D, dividends, and potential acquisitions.
4
Earnings Per Share Trend
Revenue has grown steadily; 2024 built on 2023 results.
Earnings per share show upward trend, supporting shareholder value.
The healthy dividend and consistent payout reflect commitment to returning capital.
Strong cash reserves and robust free cash flow provide flexibility for investment, R&D, dividends, and potential acquisitions.
5
Historical Revenue & EPS Trends Chart and Table
Line/bar chart of annual revenues (2018–2024)
Revenue trend shows consistent growth, demonstrating resilient demand across segments.
EPS trending upward — indicates improved profitability and efficient operations.
Dividend history chart reveals long-term commitment to shareholders.
The stock price chart contextualizes valuation relative to business performance.
6
Historical Revenue & EPS Trends Chart and Table
Line chart of EPS over same period.
Revenue trend shows consistent growth, demonstrating resilient demand across segments.
EPS trending upward — indicates improved profitability and efficient operations.
Dividend history chart reveals long-term commitment to shareholders.
The stock price chart contextualizes valuation relative to business performance.
7
Historical Revenue & EPS Trends Chart and Table
Stock price history chart 2022–2025
Revenue trend shows consistent growth, demonstrating resilient demand across segments.
EPS trending upward — indicates improved profitability and efficient operations.
Dividend history chart reveals long-term commitment to shareholders.
The stock price chart contextualizes valuation relative to business performance.
8
Historical Revenue & EPS Trends Chart and Table
Dividend history chart
Revenue trend shows consistent growth, demonstrating resilient demand across segments.
EPS trending upward — indicates improved profitability and efficient operations.
Dividend history chart reveals long-term commitment to shareholders.
The stock price chart contextualizes valuation relative to business performance.
9
Stock Price, Valuation & Market Capitalization
Share price is near the 52-week high — market seems bullish on J&J’s outlook.
A P/E around 19× is moderately priced given J&J’s stability, dividend yield, and growth prospects.
Large market cap offers liquidity and lower volatility — attractive for institutional and long-term investors.
High trading volume ensures investor ability to enter/exit positions without major price impact.
10
Current Share Price (as of December 9–10, 2025): ~ US$ 199.96 MacroTrends+1
52-Week High / Low: 52-week high ~ US$ 207.81; 52-week low ~ US$ 140.68 MacroTrends+1
Trailing P/E Ratio (TTM): ~ 19.0× CNBC+1
Forward P/E (Next 12-month estimate): ~ 16.3× CNBC
Market Capitalization: ~ US$ 428–492 B (mega-cap) CNBC+1
Average Daily Trading Volume (recent): ~8.8–10.1M shares. Twelve Data+1
Cash Flow & Liquidity Analysis
Robust operating cash flow demonstrates the company’s ability to generate cash internally, which is crucial for long-term sustainability.
Large cash reserves add financial flexibility — can be used for R&D, acquisitions, debt reduction, dividends, or to buffer downturns.
Strong free cash flow underscores shareholder value potential and supports dividend stability/increases.
11
As of end 2024: Cash & cash equivalents = approximately US$ 24.1 B. JNJ.com
2024 Cash Flow from Operations: US$ 24.3 B. JNJ.com
2025 (YTD) Free Cash Flow (non-GAAP): ~ US$ 14.2 B by Q3. JNJ.com+1
Cash flow supports dividend payments, R&D, strategic investments, and liquidity for potential acquisitions.
Dividend Policy & Shareholder Return
Attractive yield for income-oriented investors, combined with reliability (dividend increases history).
A payout ratio around 50% is conservative — implies room to maintain or raise dividends even if earnings dip.
Dividend policy signals confidence in continuing free cash flow and business stability.
12
Annual Dividend per Share: US$ 5.20 (most recent) CNBC+1
Dividend Yield: ~ 2.9% (based on current price) CNBC+1
Payout Ratio: ~ 49% of earnings — balances shareholder returns with reinvestment/retained earnings. Twelve Data+1
Long history of increasing dividends (decades of consecutive raises).
Recent Operating Results & 2025 Outlook (Q1 & Q3 2025)
Table — Recent 2025 Quarter Highlights
Projected 2025 Outlook (as of Q3 release): Revenue and EPS guidance raised (compared to prior outlook) — indicates confidence in demand and operations.
| Quarter (2025) | Reported Sales | Net Earnings (GAAP) | Diluted EPS (GAAP) | Adjusted EPS (non-GAAP) | Free Cash Flow (YTD) |
| Q1 2025 | US$ 21.89 B JNJ.com+1 | — | — | US$ 2.77 JNJ.com+1 | ~US$ 3.4 B JNJ.com+1 |
| Q3 2025 | US$ 23.99 B (6.8% YoY growth) JNJ.com | US$ 5.15 B (91% YoY growth) JNJ.com | US$ 2.12 JNJ.com | US$ 2.80 (non-GAAP) JNJ.com | ~US$ 14.2 B (YTD) JNJ.com+1 |
Strong quarter-over-quarter and year-over-year growth suggests momentum into full-year 2025.
Adjusted EPS growth and free cash flow support operational health and capital return capabilities.
Revised outlook reflects management’s confidence — positive signal for investors.
13
Risks & External Considerations
While J&J is stable and diversified, investors should remain aware of sector-specific risks (regulatory, legal, competitive).
The strategic shift to higher-margin segments offers growth potential — but also increases exposure to R&D risk and innovation cycles.
Diversification and strong cash flows help mitigate some risks but not all — prudent to monitor pipeline developments, regulatory landscape, and macro conditions.
14
Regulatory risk: pharmaceutical regulations, pricing pressure, approvals, and patent expirations could impact growth.
Litigation or legal liabilities — historically, healthcare firms face product-related lawsuits or compliance risks.
Market & macroeconomic risk: currency fluctuations (global operations), inflation, changes in healthcare policy, reimbursement rates.
Segment-specific risk: as J&J focuses more on MedTech and Innovative Medicines, success depends on innovation and competitive positioning.
Dependence on R&D and pipeline success for long-term growth; drug or device failures can affect valuation.
Strategic Proposal: New Product Initiative & Growth Opportunity
Proposal Summary:
Launch a new biologic therapy or advanced medical device (MedTech) targeting a high-need chronic condition (e.g. autoimmune disease, oncology, cardiovascular) under J&J’s R&D arm.
Rationale:
Leverage J&J’s existing R&D capabilities, global distribution channels, and cash reserves.
Diversify revenue streams beyond existing drugs/devices; capture growth in high-margin segments.
Biologics/MedTech often have higher margins and recurring demand — potential for strong long-term returns.
Supports long-term growth objectives and increases company value beyond dividends.
Expected Investor Benefits:
Potential for increased top-line growth, higher EPS, and improved P/E multiple.
Enhances portfolio for growth-oriented investors (not just income investors).
Signals commitment to innovation — may boost investor confidence and attract broader investor base.
Given J&J’s financial strength and track record, launching a new product is feasible and likely to be well-supported.
This strategy aligns with current company focus on Innovative Medicines and MedTech.
Emphasize that this is a long-term investment — benefits may accrue over several years, but risk-adjusted returns could be substantial.
15
Valuation & Investment Recommendation
Solid fundamentals: growing revenue, rising EPS, strong cash flow, healthy balance sheet (cash reserves).
Reliable dividend with long history and attractive yield — good for income investors.
Large market cap, diversified business, global footprint — lower volatility and safer than many high-risk equities.
Growth potential via strategic initiatives (new product launch), plus stability through dividend returns.
Balanced risk/reward: while regulatory and sector risks exist, diversification and financial strength mitigate downside.
For conservative investors seeking income + stability — J&J is well-suited.
For growth-focused investors — the proposed new product strategy provides upside.
Recommend building or maintaining a core position in J&J as a blue-chip, dividend-paying stock with growth upside.
16
Relating Stock Price, P/E & Market Cap to Investor Value
Current P/E (~19×) reflects market confidence in continued earnings and growth — not overly aggressive, reasonable for a large stable company.
Market cap in the high hundreds of billions USD underscores scale, liquidity, and stability.
For investors, this translates to: lower risk, good liquidity, accessible entry/exit, predictable returns (dividends + potential capital appreciation).
Emphasize that valuation is in line with peers in the healthcare/pharma/MedTech sector, and given fundamentals, appears justified.
Large market cap helps reduce company-specific risk — macroeconomic or sector shifts less likely to severely impact compared to small-cap firms.
Stock offers a balance: stability + income + potential for growth — a good anchor for diversified portfolios.
17
Summary and Final Recommendation
Johnson & Johnson is financially strong: growing revenue and EPS, robust cash flow, large cash reserves.
Long-standing commitment to dividends — attractive to income-seeking investors.
Market valuation (price, P/E, market cap) reflects a stable, blue-chip status — fairly priced given fundamentals.
Strategic shift toward high-margin segments (pharma & MedTech) enhances growth potential.
Proposed new product initiative could further boost long-term growth and shareholder value.
Final Recommendation: Buy (or Hold) — J&J represents a solid core investment: stable income, moderate growth, and lower risk compared to high-volatility equities
Recommend building or increasing position for long-term investors looking for a mix of income and growth.
Suggest periodic review (quarterly/annually) to monitor pipeline developments, regulatory environment, and financial performance.
For a balanced portfolio, J&J can serve as a stable core holding complemented by more aggressive growth stocks.
18
References & Data Sources
Johnson & Johnson — Q4 2024 and Full-Year 2024 Results. JNJ.com
Johnson & Johnson — Q3 2025 Results (sales, EPS, free cash flow). JNJ.com+1
Johnson & Johnson — Q1 2025 Results Summary. JNJ.com+1
Johnson & Johnson — 2024 Annual Report (Liquidity & Cash Flows). JNJ.com
Stock price history and 52-week high/low data: Macrotrends & public market-data sources. MacroTrends+1
Market statistics (P/E, yield, volume, market cap, shares outstanding): public market-data summaries.
References
19
